Is Buying Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), Having Higher Short Interest a Winning Strategy?

May 10, 2018 - By marketbeat

The stock of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) registered an increase of 50.03% in short interest. MDGL’s total short interest was 1.26 million shares in May as published by FINRA. Its up 50.03% from 838,300 shares, reported previously. With 362,600 shares average volume, it will take short sellers 4 days to cover their MDGL’s short positions. The short interest to Madrigal Pharmaceuticals Inc’s float is 21.3%.

The stock decreased 3.92% or $4.62 during the last trading session, reaching $113.25. About 163,775 shares traded. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has risen 574.52% since May 10, 2017 and is uptrending. It has outperformed by 562.97% the S&P500.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company has market cap of $1.61 billion. The company’s lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It currently has negative earnings. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials.

More recent Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) news were published by: which released: “Lucky Seven: An Introduction To My Top Biotechnology Picks” on May 03, 2018. Also published the news titled: “Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements” on May 08, 2018.‘s news article titled: “William Blair Initiates Viking With An Outperform Rating After Competitor Proves Strategy” with publication date: April 30, 2018 was also an interesting one.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: